MOLOGEN AG confirmed its outlook for the 2015 financial year. In view of the progress made in ongoing study programs, a significant year-on-year increase in R&D expenses is still expected for the 2015 financial year. This will lead to a higher net loss for 2015.
1st Jan change | Capi. | |
---|---|---|
+1.51% | 42.75B | |
+49.22% | 41.61B | |
+8.57% | 41.34B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |